4,490 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by iSAM Funds UK Ltd

iSAM Funds UK Ltd purchased a new position in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,490 shares of the company’s stock, valued at approximately $732,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC bought a new stake in shares of Zoetis in the 4th quarter valued at $30,000. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis in the 4th quarter valued at $44,000. Finally, Asset Planning Inc bought a new stake in shares of Zoetis in the 4th quarter valued at $58,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of several research analyst reports. Barclays lifted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. UBS Group lowered their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus price target of $212.75.

Zoetis Price Performance

ZTS opened at $163.90 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $72.97 billion, a price-to-earnings ratio of 29.96, a P/E/G ratio of 2.78 and a beta of 0.94. The firm’s fifty day moving average price is $156.51 and its two-hundred day moving average price is $165.09. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.38 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. The trade was a 2.02% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.18% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.